파상풍 톡소이드 백신 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the tetanus toxoid vaccine market size in 2026 is estimated at USD 6.47 billion, growing from 2025 value of USD 6.13 billion with 2031 projections showing USD 8.49 billion, growing at 5.59% CAGR over 2026-2031.

This report is Segmented by Vaccine Type (Diphtheria, Tetanus, and Pertussis (DTaP), and More), Age Group (Paediatric (0-16 Yrs), and More), End-User (Hospitals & Trauma Centres, and More), Distribution Channel (Government Procurement, and More) and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Tetanus Toxoid Vaccine Market Trends and Insights

Expansion of National Immunisation Programmes & Booster Policy Updates

Global programmes now emphasise cradle-to-senior coverage, supported by WHO's Immunization Agenda 2030 that targets 90% DTP3 coverage. Countries such as South Sudan reaffirmed this approach during African Vaccination Week 2025, pairing new vaccine launches with tetanus-booster outreach. 'The Big Catch-Up' campaign seeks to close pandemic-era gaps among under-fives, while many ministries are embedding adolescent and adult boosters into schedules, enlarging the addressable segments of the tetanus toxoid vaccine market. These broadened policies underpin forecasts for incremental multi-age demand over the medium term and provide tailwinds for manufacturers positioned with life-course formulations.

Growing Adoption of Pentavalent & Hexavalent Combination Vaccines

Higher-valent combinations shorten clinic visits, lift completion rates and simplify logistics. Evidence shows children receiving combination vaccines achieve superior on-time coverage. CanSino's DTcP candidate holds Chinese priority-review status, while its DTcP-Hib-MCV4 product entered clinical trials in February 2025 . Annual pentavalent demand is projected at 135 million doses across 2023-2025 in transitioning middle-income economies. The ability to dovetail diphtheria, pertussis and tetanus antigens into a single shot reinforces the tetanus toxoid vaccine market's combination pivot and is expected to dominate long-term growth.

Vaccine Hesitancy & Misinformation Undermining Uptake Across All Age Groups

Declining trust in institutions and circulating myths depress uptake. Fourteen-and-a-half million children missed routine vaccines in 2023, many in fragile settings. Adult boosters suffer from low prioritisation; surveys indicate awareness gaps about decennial Td/Tdap schedules. Lower demand translates into expired stock, complicating inventory planning and undermining efficient delivery within the tetanus toxoid vaccine market.

Other drivers and restraints analyzed in the detailed report include:

1. Sustained Procurement Funding from UNICEF, Gavi & PAHO Revolving Fund
2. Rising Awareness of Adult Booster Immunisation in Developed & Emerging Markets
3. Entry of Cost-competitive Manufacturers via WHO Prequalification Pathway
4. Advancements in Low-dose Adjuvant & Thermostable Formulation Technologies
5. Concentrated Manufacturing Base Creating Supply-chain Vulnerability

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

DTaP secured 41.35% of tetanus toxoid vaccine market share in 2025 on the back of five-dose paediatric schedules. The tetanus toxoid vaccine market size for this segment is forecast to exhibit mid-single-digit growth as guidelines remain unchanged. Tdap's 7.75% CAGR outpaces the wider market because adolescent, maternal and adult boosters are scaling; CDC endorses Tdap during every pregnancy, with >90% infant pertussis protection.

Standalone TT products are declining as tenders pivot to Td, and mRNA DTP prototypes could disrupt pricing and manufacturing paradigms by late forecast. The tetanus toxoid vaccine industry therefore concentrates R&D on higher-valent, thermostable or genetic-platform formulations to preserve relevance amid evolving schedules.

Paediatrics held 84.30% share of the tetanus toxoid vaccine market size in 2025, sustained by school-entry mandates and VFC entitlements. Nonetheless, adults show a 6.33% CAGR as immunosenescence and injury-prone lifestyles highlight booster gaps. Evidence of disproportionate tetanus cases among seniors with lapsed immunity underscores an unmet need.

Policy levers such as Medicare cost caps remove financial barriers, while rapid saliva testing enables targeted outreach within minutes. These factors collectively reposition the adult cohort as a growth lever in the tetanus toxoid vaccine market.

Complete Report Scope:

• By Vaccine Type
  • Diphtheria, Tetanus, and Pertussis (DTaP)
  • Diphtheria and Tetanus (DT)
  • Tetanus, Diphtheria, And Pertussis (Tdap)
  • Other Vaccine Types
• By Age Group
  • Paediatric (0-16 yrs)
  • Adult (>16 yrs)
• By End User
  • Hospitals & Trauma Centres
  • Public Immunisation Clinics & EPI Sites
  • Other End Users
• By Distribution Channel
  • Government Procurement
  • Private / Self-pay
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle-East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America delivered 35.60% of 2025 revenue, supported by mature coverage systems and the Inflation Reduction Act's zero cost-share adult vaccine clause. Nonetheless, the 2024 Td shortfall revealed vulnerabilities and forced clinics to substitute with Tdap in certain settings. California has intensified Tdap outreach amid pertussis spikes, especially targeting pregnancies week 27-36. Sustained legislative and funding support maintain the region's central role in the tetanus toxoid vaccine market.

Asia Pacific stands out with a 7.12% CAGR to 2031. India supplies 60% of vaccines for global immunisation programmes, while China covers 90% of its domestic need. Government incentives and WHO prequalification pathways bolster exports. Vietnam's private vaccine turnover above USD 300 million underscores rising middle-class demand. Regional capacity-Serum Institute's 3 billion doses and Bharat Biotech's 4 billion-supports scalable supply, underscoring the region's next-wave influence on the tetanus toxoid vaccine market.

Europe, the Middle East, Africa and South America exhibit heterogeneous drivers. Europe maintains high coverage but confronts pockets of hesitancy. Forty-seven of 59 high-risk nations have now eliminated maternal and neonatal tetanus, many in Africa, reflecting successful donor-backed drives. AVMA's USD 1 billion initiative seeks to lift Africa's share of global output beyond today's 0.2%. PAHO bulk-procurement models stabilise South American pricing. Collectively these regions broaden geographic diversity and mitigate concentration risks within the tetanus toxoid vaccine market.

1. Sanofi (Sanofi Pasteur)
2. GlaxoSmithKline
3. Pfizer
4. Merck
5. Serum Institute of India
6. Bharat Biotech International Ltd.
7. Biological E Ltd.
8. Panacea Biotec Ltd.
9. BB-NCIPD Ltd.
10. PT Bio Farma (Persero)
11. Emergent Bio Solutions
12. LG Chem
13. Sinopharm Group Co., Ltd.
14. Sinovac Biotech
15. KM Biologics (Mitsubishi Tanabe)
16. Seqirus (CSL Ltd.)
17. Aurobindo Pharma Ltd. (Vaccines Div.)
18. Valneva

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Expansion of National Immunisation Programmes & Booster Policy Updates
  • 4.2.2 Growing Adoption of Pentavalent & Hexavalent Combination Vaccines
  • 4.2.3 Sustained Procurement Funding from UNICEF, Gavi & PAHO Revolving Fund
  • 4.2.4 Rising Awareness of Adult Booster Immunisation in Developed & Emerging Markets
  • 4.2.5 Entry of Cost-competitive Manufacturers via WHO Prequalification Pathway
  • 4.2.6 Advancements in Low-dose Adjuvant & Thermostable Formulation Technologies
• 4.3 Market Restraints
  • 4.3.1 Vaccine Hesitancy & Misinformation Undermining Uptake Across All Age Groups
  • 4.3.2 Concentrated Manufacturing Base Creating Supply-chain Vulnerability
  • 4.3.3 Budgetary Constraints for Td/Tdap Transition in Low- & Middle-Income Countries
  • 4.3.4 Adverse Events & Litigation Risks Linked to Combination Vaccines
• 4.4 Regulatory Outlook
• 4.5 Porter's Five Forces Analysis
  • 4.5.1 Threat of New Entrants
  • 4.5.2 Bargaining Power of Buyers (UNICEF, PAHO Revolving Fund)
  • 4.5.3 Bargaining Power of Suppliers
  • 4.5.4 Threat of Substitutes (Hyper-immune Globulin, mRNA)
  • 4.5.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Vaccine Type
  • 5.1.1 Diphtheria, Tetanus, and Pertussis (DTaP)
  • 5.1.2 Diphtheria and Tetanus (DT)
  • 5.1.3 Tetanus, Diphtheria, And Pertussis (Tdap)
  • 5.1.4 Other Vaccine Types
• 5.2 By Age Group
  • 5.2.1 Paediatric (0-16 yrs)
  • 5.2.2 Adult (>16 yrs)
• 5.3 By End User
  • 5.3.1 Hospitals & Trauma Centres
  • 5.3.2 Public Immunisation Clinics & EPI Sites
  • 5.3.3 Other End Users
• 5.4 By Distribution Channel
  • 5.4.1 Government Procurement
  • 5.4.2 Private / Self-pay
• 5.5 Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle-East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Strategic Moves
• 6.3 Market Share Analysis
• 6.4 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.4.1 Sanofi (Sanofi Pasteur)
  • 6.4.2 GSK plc
  • 6.4.3 Pfizer Inc.
  • 6.4.4 Merck & Co., Inc.
  • 6.4.5 Serum Institute of India Pvt. Ltd.
  • 6.4.6 Bharat Biotech International Ltd.
  • 6.4.7 Biological E Ltd.
  • 6.4.8 Panacea Biotec Ltd.
  • 6.4.9 BB-NCIPD Ltd.
  • 6.4.10 PT Bio Farma (Persero)
  • 6.4.11 Emergent BioSolutions Inc.
  • 6.4.12 LG Chem Ltd.
  • 6.4.13 Sinopharm Group Co., Ltd.
  • 6.4.14 Sinovac Biotech Ltd.
  • 6.4.15 KM Biologics (Mitsubishi Tanabe)
  • 6.4.16 Seqirus (CSL Ltd.)
  • 6.4.17 Aurobindo Pharma Ltd. (Vaccines Div.)
  • 6.4.18 Valneva SE

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment